683 Capital Management’s C4 Therapeutics CCCC Stock Holding History

683 Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$789K	–	171
2026 Q1	$789K	Sell	300,000 -100,000	-25%	-$235K	0.04%	150
2025 Q4	$764K	Buy	+400,000	New	+$948K	0.03%	163
2024 Q1	–	Sell	-55,602	Closed	-$314K	–	161
2023 Q4	$314K	Buy	+55,602	New	+$127K	0.03%	116

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

683 Capital Management's CCCC Position: Q2 2026 in Review

683 Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 300,000 shares — an estimated $789K sold.

683 Capital Management first reported a position in CCCC in Q4 2023 and held it in 3 quarters. The position peaked at $789K in Q1 2026. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

683 Capital Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
683 Capital Management sold 300,000 C4 Therapeutics shares in Q2 2026, an estimated $789K.
683 Capital Management first reported a position in C4 Therapeutics in Q4 2023 and held it in 3 quarters.
683 Capital Management's C4 Therapeutics position peaked at $789K in Q1 2026.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.